{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:21:18Z","timestamp":1768432878698,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10067-016-3351-5","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T06:16:25Z","timestamp":1468908985000},"page":"2841-2845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Premedication prevents infusion reactions and improves retention rate during infliximab treatment"],"prefix":"10.1007","volume":"35","author":[{"given":"Francesca","family":"Bartoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cometi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Blagojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginevra","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tofani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Galluccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"issue":"Suppl 2","key":"3351_CR1","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","volume":"72","author":"DE Furst","year":"2013","unstructured":"Furst DE, Keystone EC, So AK, Braun J, et al. (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 72(Suppl 2):ii2\u2013i34","journal-title":"Ann Rheum Dis"},{"key":"3351_CR2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","volume":"159","author":"LL Lecluse","year":"2008","unstructured":"Lecluse LL, Piskin G (2008) Review and expert opinion on prevention and treatment of infliximab-related infusion reaction. Br J Dermatol 159:527\u2013536","journal-title":"Br J Dermatol"},{"key":"3351_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","volume":"34","author":"C Steenholdt","year":"2011","unstructured":"Steenholdt C, Svenson M, Bendtzen K, et al. (2011) Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 34:51\u201358","journal-title":"Aliment Pharmacol Ther"},{"key":"3351_CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2010.136283","volume":"70","author":"A Okuyama","year":"2011","unstructured":"Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, Takeuchi T (2011) Fc\u03b3 receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:299\u2013304","journal-title":"Ann Rheum Dis"},{"key":"3351_CR5","first-page":"1307","volume":"33","author":"T Lequerr\u00e9","year":"2006","unstructured":"Lequerr\u00e9 T, Vittecoq O, Klemmer N, et al. (2006) Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33:1307\u20131314","journal-title":"J Rheumatol"},{"key":"3351_CR6","first-page":"S73","volume":"17","author":"C Antoni","year":"1999","unstructured":"Antoni C, Kalden JR (1999) Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 17:S73\u2013S77","journal-title":"Clin Exp Rheumatol"},{"key":"3351_CR7","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98:1315\u20131324","journal-title":"Am J Gastroenterol"},{"key":"3351_CR8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0210-5705(08)75809-6","volume":"31","author":"F Bermejo","year":"2008","unstructured":"Bermejo F, Lopez San Roman A, Algaba A, Van Domselaar M, Carneros JA, Rivero M, et al. (2008) Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab. Gastroenterol Hepatol 31:629\u2013632","journal-title":"Gastroenterol Hepatol"},{"key":"3351_CR9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard.2005.037499","volume":"64","author":"J Sany","year":"2005","unstructured":"Sany J, Kaiser MJ, Jorgensen C, et al. (2005) Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 64:1647\u20131649","journal-title":"Ann Rheum Dis"},{"key":"3351_CR10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. (2004) Infliximab induction therapy for patients with severe plaque type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534\u2013542","journal-title":"J Am Acad Dermatol"},{"key":"3351_CR11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. (2005) Infliximab induction and maintenance therapy for moderate to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374","journal-title":"Lancet"},{"key":"3351_CR12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, et al. (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711\u2013715","journal-title":"Arthritis Rheum"},{"key":"3351_CR13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 348:601\u2013608","journal-title":"N Engl J Med"},{"key":"3351_CR14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Jeen YT, et al. (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 124:917\u2013924","journal-title":"Gastroenterology"},{"key":"3351_CR15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol 2:542\u2013553","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3351-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:42:15Z","timestamp":1498329735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3351-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}